迈瑞掌门人李西廷连续增持超亿元，更大动作还在后面！

Core Viewpoint - The continuous share buybacks by the chairman of Mindray Medical reflect confidence in the company's future growth and recovery in performance despite recent challenges [1][2] Group 1: Share Buyback Activity - Chairman Li Xiting increased his stake in Mindray Medical by purchasing 150,600 shares at an average price of 199.12 yuan per share, totaling 29.99 million yuan [1] - Li Xiting has made four consecutive share purchases, with a cumulative investment exceeding 100 million yuan [1] - The chairman plans to invest an additional 200 million yuan in the next six months without a price range, indicating a strong commitment to the company's future [1] Group 2: Company Performance and Strategy - Despite facing pressure in the first three quarters of 2025 due to high base effects, Mindray Medical reported a year-on-year revenue growth of 1.53% in the third quarter, signaling a potential turning point [1] - The company believes the most challenging period for its domestic business has passed and is focusing on increasing market share, particularly in the IVD sector [2] - Mindray Medical is prioritizing resource allocation towards high-value consumables and international markets, with expectations for significant growth in these areas [2] - The company aims to break into the top 20 global medical device rankings, maintaining a top-three market share in key product categories [2]